RATIONALE: NADPH oxidases (Noxes) regulate vascular physiology and contribute to the pathogenesis of vascular disease. In vascular smooth muscle cells (VSMCs), the interactions of individual Nox homologs with regulatory proteins are poorly defined. OBJECTIVE: The objective of this study was to identify novel NADPH oxidase regulatory proteins. METHODS AND RESULTS: Using a yeast 2-hybrid screen, we identified a novel p22phox binding partner, Poldip2, and demonstrated that it associates with p22phox, NADPH oxidase (Nox)1, and Nox4 and colocalizes with p22phox at sites of Nox4 localization. Poldip2 increases Nox4 enzymatic activity by 3-fold and positively regulates basal reactive oxygen species production in VSMCs (O2(.-): 86.3+/-15.6% increase; H2O2: 40.7+/-4.5% increase). Overexpression of Poldip2 activates Rho (180.2+/-24.8% increase), strengthens focal adhesions, and increases stress fiber formation. These phenotypic changes are blocked by dominant negative Rho. In contrast, depletion of either Poldip2 or Nox4 results in a loss of these structures, which is rescued by adding back active Rho. Cell migration, which requires dynamic cytoskeletal remodeling, is impaired by either excess (70.1+/-14.7% decrease) or insufficient Poldip2 (63.5+/-5.9% decrease). CONCLUSIONS: These results suggest that Poldip2 associates with p22phox to activate Nox4, leading to regulation of focal adhesion turnover and VSMC migration, thus linking reactive oxygen species production and cytoskeletal remodeling. Poldip2 may be a novel therapeutic target for vascular pathologies with a significant VSMC migratory component, such as restenosis and atherosclerosis.
RATIONALE: NADPH oxidases (Noxes) regulate vascular physiology and contribute to the pathogenesis of vascular disease. In vascular smooth muscle cells (VSMCs), the interactions of individual Nox homologs with regulatory proteins are poorly defined. OBJECTIVE: The objective of this study was to identify novel NADPH oxidase regulatory proteins. METHODS AND RESULTS: Using a yeast 2-hybrid screen, we identified a novel p22phox binding partner, Poldip2, and demonstrated that it associates with p22phox, NADPH oxidase (Nox)1, and Nox4 and colocalizes with p22phox at sites of Nox4 localization. Poldip2 increases Nox4 enzymatic activity by 3-fold and positively regulates basal reactive oxygen species production in VSMCs (O2(.-): 86.3+/-15.6% increase; H2O2: 40.7+/-4.5% increase). Overexpression of Poldip2 activates Rho (180.2+/-24.8% increase), strengthens focal adhesions, and increases stress fiber formation. These phenotypic changes are blocked by dominant negative Rho. In contrast, depletion of either Poldip2 or Nox4 results in a loss of these structures, which is rescued by adding back active Rho. Cell migration, which requires dynamic cytoskeletal remodeling, is impaired by either excess (70.1+/-14.7% decrease) or insufficientPoldip2 (63.5+/-5.9% decrease). CONCLUSIONS: These results suggest that Poldip2 associates with p22phox to activate Nox4, leading to regulation of focal adhesion turnover and VSMC migration, thus linking reactive oxygen species production and cytoskeletal remodeling. Poldip2 may be a novel therapeutic target for vascular pathologies with a significant VSMC migratory component, such as restenosis and atherosclerosis.
Authors: Kendra D Martyn; Linda M Frederick; Katharina von Loehneysen; Mary C Dinauer; Ulla G Knaus Journal: Cell Signal Date: 2005-05-31 Impact factor: 4.315
Authors: B Lassègue; D Sorescu; K Szöcs; Q Yin; M Akers; Y Zhang; S L Grant; J D Lambeth; K K Griendling Journal: Circ Res Date: 2001-05-11 Impact factor: 17.367
Authors: Lula L Hilenski; Roza E Clempus; Mark T Quinn; J David Lambeth; Kathy K Griendling Journal: Arterioscler Thromb Vasc Biol Date: 2003-12-11 Impact factor: 8.311
Authors: David S Weber; Yoshihiro Taniyama; Petra Rocic; Puvi N Seshiah; Melissa A Dechert; William T Gerthoffer; Kathy K Griendling Journal: Circ Res Date: 2004-04-01 Impact factor: 17.367
Authors: Moo Yeol Lee; Alejandra San Martin; Puja K Mehta; Anna E Dikalova; Abel Martin Garrido; S Raju Datla; Erin Lyons; Karl-Heinz Krause; Botond Banfi; J David Lambeth; Bernard Lassègue; Kathy K Griendling Journal: Arterioscler Thromb Vasc Biol Date: 2009-01-15 Impact factor: 8.311
Authors: Howard E Boudreau; Benjamin W Casterline; Balazs Rada; Agnieszka Korzeniowska; Thomas L Leto Journal: Free Radic Biol Med Date: 2012-06-19 Impact factor: 7.376
Authors: Abel Martin-Garrido; David I Brown; Alicia N Lyle; Anna Dikalova; Bonnie Seidel-Rogol; Bernard Lassègue; Alejandra San Martín; Kathy K Griendling Journal: Free Radic Biol Med Date: 2010-11-11 Impact factor: 7.376
Authors: Luciana A Pescatore; Diego Bonatto; Fábio L Forti; Amine Sadok; Hervé Kovacic; Francisco R M Laurindo Journal: J Biol Chem Date: 2012-07-06 Impact factor: 5.157
Authors: Pamela W M Kleikers; K Wingler; J J R Hermans; I Diebold; S Altenhöfer; K A Radermacher; B Janssen; A Görlach; H H H W Schmidt Journal: J Mol Med (Berl) Date: 2012-10-23 Impact factor: 4.599
Authors: Christa Caesar; Alicia N Lyle; Giji Joseph; Daiana Weiss; Fadi M F Alameddine; Bernard Lassègue; Kathy K Griendling; W Robert Taylor Journal: Cell Mol Bioeng Date: 2016-12-27 Impact factor: 2.321
Authors: Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner Journal: Antioxid Redox Signal Date: 2014-01-24 Impact factor: 8.401
Authors: Derick Okwan-Duodu; Laura Hansen; Giji Joseph; Alicia N Lyle; Daiana Weiss; David R Archer; W Robert Taylor Journal: Arterioscler Thromb Vasc Biol Date: 2018-03-15 Impact factor: 8.311